You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Galactose

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Galactose?

Galactose is an investigational drug.

There have been 22 clinical trials for Galactose. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Syndrome, Mucopolysaccharidosis IV, and Mucopolysaccharidoses. The leading clinical trial sponsors are BioMarin Pharmaceutical, University of Aarhus, and Aarhus University Hospital.

There are two US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for Galactose
Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 GangliosidosisAxovant Sciences, Inc.Phase 1/Phase 2
Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 GangliosidosisNational Human Genome Research Institute (NHGRI)Phase 1/Phase 2
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic GalactosemiaApplied Therapeutics, Inc.Phase 1/Phase 2

See all Galactose clinical trials

Clinical Trial Summary for Galactose

Top disease conditions for Galactose
Top clinical trial sponsors for Galactose

See all Galactose clinical trials

US Patents for Galactose

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galactose   Start Trial Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA)   Start Trial
Galactose   Start Trial Prokaryotic xylose isomerase for the construction of xylose-fermenting yeasts LESAFFRE ET COMPAGNIE (Paris, FR)   Start Trial
Galactose   Start Trial Methods and systems for growing plants using silicate-based substrates, cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives, and formulations, processes and systems for the same Innovation Hammer, LLC (Powell, OH)   Start Trial
Galactose   Start Trial Multiuse, enzymatic detergent and methods of stabilizing a use solution Ecolab USA Inc. (Saint Paul, MN)   Start Trial
Galactose   Start Trial Optical nanosensors comprising photoluminescent nanostructures MASSACHUSETTS INSTITUTE OF TECHNOLOGY (Cambridge, MA)   Start Trial
Galactose   Start Trial Humanized anti-Tn-MUC1 antibodies and their conjugates ADC Therpeutics S.A. (Epalinges, CH) Medimmune Limited (Cambridge, GB)   Start Trial
Galactose   Start Trial Probiotic Bifidobacterium adolescentis strains CHR. Hansen A/S (Hoersholm, DK)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galactose

Drugname Country Document Number Estimated Expiration Related US Patent
Galactose World Intellectual Property Organization (WIPO) 2013071079 2031-11-09   Start Trial
Galactose Australia 2009266009 2028-07-02   Start Trial
Galactose Brazil PI0913845 2028-07-02   Start Trial
Galactose Canada 2728682 2028-07-02   Start Trial
Galactose Germany 102008031350 2028-07-02   Start Trial
Galactose Denmark 2313495 2028-07-02   Start Trial
Galactose European Patent Office 2313495 2028-07-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.